In 1950 and 1951 two unknown radioiodinebearing compounds were observed (1-3) on chromatograms of plasma obtained from animals treated with I'31. Gross and Pitt-Rivers (4) identified one of these as 3,5,3'-l-triiodothyronine, which they had previously isolated (5) from the plasma of euthyroid and hyperthyroid individuals treated with 131". They excluded the possibility of analytical or radiation artefact and considered 3,5,3'-l-triiodothyronine to be a normal constituent of the organic iodine moiety of plasma. Concomitantly, Roche, Lissitzky, and Michel (6) reported the conversion in vitro of diiodothyronine to triiodothyronine and crystallization of the latter compound. On the basis of its ability to prevent goiter in rats treated with thiouracil, Gross and Pitt-Rivers (7) found triiodothyronine three times as active as thyroxine. They also demonstrated its effectiveness (8) in raising the metabolic rate and correcting the symptoms of myxedema in two patients. In this respect they considered it to be at least as calorigenic as 1-thyroxine and probably more so, and suggested that it might prove to be the tissue form of the thyroid hormone.
amino acid to be found thus far which possesses hormonal properties comparable in intensity to those of thyroxine, it appeared desirable to make qualitative and quantitative comparison of the calorigenic properties of the two substances in human subjects.
METHOD
Eight persons with untreated myxedema who served as volunteers were hospitalized throughout the study. Duplicate determinations of the basal metabolic rate using the closed-chamber method were made daily except Sunday. Before the tests were made, the basal 'The Mayo Foundation is a part of the Graduate School of the University of Minnesota. metabolic rate was determined daily for 6 to 16 days to establish a satisfactory base line. Serum-protein-bound iodine was estimated by the method of Barker (9) .
Triiodothyronine and thyroxine 2 were administered in a small volnme of sterile physiologic saline solution in which the substance was dissolved with the aid of sufficient sodium hydroxide. A single injection of the amino acid to be tested was given intravenously after the morning metabolic rate had been determined. Daily observations were then continued for as long as possible, in most instances until the curve depicting the basal metabolic rate had returned to a level within 1 or 2 calories per hour of the original base line. Careful record was made of clinical reaction and symptoms following the injections. Serum-protein-bound iodine was also determined at several intervals after injection.
In accordance with a procedure previously employed by other investigators (10, 11) , mean daily metabolic rates were expressed as calories per day rather than as calories per hour. For each day following injection the mean base line obtained during the initial control period was then substracted from each daily value. The difference was considered to represent the increment in calories produced by the hormone being studied.
Each subject underwent two to six individual studies. In all, the effects of 18 doses of triiodothyronine and 11 doses of thyroxine were studied, involving a total of 1,213 determinations of basal metabolic rate. The data are summarized in Table I .
RESULTS
Following injection of either substance, the basal metabolic rate responded initially by rising to a peak value and subsequently by declining gradually toward the original base line (Figure 1 ). The decline of metabolic rate following injection of either drug could be fitted to a straight line when plotted on semilogarithmic paper versus time. With doses in excess of 4 micrograms per kilogram of body weight, triiodothyronine invariably produced subjective discomfort including malaise, restlessness, generalized aching, muscular and joint pain, loss of appetite, and headache. When the dose exceeded 10 micrograms per kilogram, these symptoms became intense. The symptoms accompanied the period of maximal metabolic response and, in most instances, subsided by the third or fourth day. These symptoms were identical with those often encountered in myxedematous patients whose metabolic rate is being rapidly elevated by administration of desiccated thyroid.
In contrast to the striking subj ective discomnfort following injection of triiodothyronine, similar symptoms did not occur after the administration of thyroxine in the doses here employed, although such symptoms have previously been observed to follow larger doses ( 10 imig. dl-thyroxine) given intravenously (10) .
The curves depicting the effect of intravenous doses of each substance upon the metabolic rate were compared from four standpoints: (1) Table I ).
Because of the difference in temporal relations observed with) the two substances, the most significant basis for comparing their over-all effects appeared likely to be the total integrated caloric response (Ctet) represented by the total area under each curve of caloric response versus time. The area of the initial limb and the observed portion of the descending limb could be calculated by application of the trapezoidal rule. Since the descending limb of each such curve fitted a simple exponential function, it was possible to estimate a correction for the small residue of calorigenic activity remaining at the end of the period of observation and, in addition, for the residue of calorigenic activity remaining at the onset from any previous injection. Times of observation were arranged so that such corrections with few exceptions represented less than 10 per cent of the total area under each curve.
A dose-response curve constructed from such observations ( Figure 3 ) indicated that when the dose was small the total caloric response resulting from an injection of l-triiodothyronine exceeded the response produced by an equimolar amount of 1-thyroxine. However, with larger doses the reverse was true, that is, the total caloric response produced by thyroxine was greater.
The effect of the injections on protein-bound iodine can be judged from Figure 4 . These studies indicate that results obtained with this method are reproducible and that successive doses may be evaluated accurately in the same subject providing sufficient time has elapsed between them. Investigators (11), in 1929, found a striking difference in the effectiveness of 10 mg. of intravenously administered racemic thyroxine at a basal metabolic level of -40 per cent compared with the biologic effectiveness of the same dose at a metabolic level of -4 per cent. However, they were comparing metabolic levels which differed by 20 or more calories per hour whereas in our study most comparisons were made at metabolic levels which did not differ by more than 1 calorie per hour.
In comparable doses, triiodothyronine was found to have an early and large maximal effect which disappeared rapidly whereas thyroxine exhibited a more delayed and less intense maximal effect which persisted for a longer interval. The more intense maximal effect of triiodothyronine frequently produced annoying subjective symptoms. These were not encountered with thyroxine except in doses much larger than those employed in this study. These qualitative differences posed practical obstacles to the bio-assay in man of small doses of thyroxine or large doses of triiodothyronine. Thyroxine could not be tested in doses of less than 300 micrograms because such doses did not produce sufficient elevation of the basal metabalic rate. Large doses of triiodothyronine could not be evaluated with safety because of the disturbing subjective symptoms. Therefore, single-doses of the two drugs could be compared directly only in the. dose.range of 0.3 to 1.0 mg. Within this range of dosage the dose-response relationships of single injections of the two hormones have been compared in two ways. On the basis 6f maximal The changes which were observed in proteinbound iodine following injections of triiodothyronine and thyroxine could reflect more rapid destruction of triiodothyronine, a larger volume of distribution, or both, than in the case of thyroxine. Preliminary studies with radioactive triiodothyronine suggest that both phenomena are involved. A wider distribution of triiodothyronine could easily explain its more immediate calorigenic effect. If one accepts the premise that a hormone is metabolized in the course of exerting its effect, more rapid destruction would be expected, which might also be compatible with a shorter duration of action. These comparisons are compatible with the suggestion of Gross, Pitt-Rivers and Trotter (8) that triiodothyronine may be the tissue form of thyroid hormone, but do not provide any direct proof of such a theory.
SUMMARY
The calorigenic effect of single intravenous doses of l-triiodothyronine and 1-thyroxine has been compared in eight subjects having myxedema. Following administration of l-triiodothyronine the basal metabolism rose more quickly to a maximal value, and subsequently fell toward the base line more rapidly than following administration of 1-thyroxine. The mean time elapsing between injection and maximal metabolic rate was 2.2 + 0.1 days in the case of the formler and 9.4 + 0.9 days in the case of the latter. After a maximiial value was reached, both curves decreased exponentially, the half-value time for triiodothyronine being 7.4 + 0.6 and for thyroxine 11.9 + 0.4 days. When compared on the basis of the maximal metabolic rate resulting from a given injection, triiodothyronine appeared to be three or four times as potent as thyroxine. On the basis of total calories added to the base line throughout the duration of action of each injection, the dose-response curves of the two substances were not parallel. On this basis, with small doses, triiodothyronine was more calorigenic than thyroxine btut with larger doses (above about 10 micrograms per kilogram of body weight) thyroxine was more effective than triiodothyronine.
